18 November, 2025 in Investor Relations Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
13 November, 2025 in Investor Relations Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
05 November, 2025 in Investor Relations Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
